- Among patients who had a colonoscopy, statin use was associated with a lower risk for diagnosis of colorectal cancer (CRC) in the following 3 years (PCCRC-3y).
Why this matters
- The potential risk reduction could help guide clinical decision-making regarding statin prescription in patients at high risk for CRC and borderline cardiovascular risk.
- Retrospective analysis of 187,897 patients in Hong Kong who underwent colonoscopy between 2005 and 2013.
- Funding: None disclosed.
- Propensity score matching between 17,662 statin users and 30,304 nonusers showed statin use was associated with a lower risk for PCCRC-3y (subdistribution HR [SHR], 0.72; 95% CI, 0.55-0.95; number needed to treat, 498).
- Statin use was associated with:
- Lower risk for proximal CRC (SHR, 0.50; 95% CI, 0.28-0.91), but not distal CRC (SHR, 0.80; 95% CI, 0.59-1.09).
- A dose-dependent reduction in PCCRC-3y risk (SHR, 0.93; 95% CI, 0.87-0.99; for every 100 increase in cumulative defined daily dose; P=.023).
- Lower PCCRC-3y risk in patients aged ≥60 years (SHR, 0.72; 95% CI, 0.56-0.92), women (SHR, 0.35; 95% CI, 0.22-0.58), nondiabetic patients (SHR, 0.59; 95% CI, 0.42-0.81), and patients with no history of polyps and/or polypectomy (SHR, 0.58; 95% CI, 0.41-0.83).
- Asian population.
- Retrospective analysis.